Shigeru Suga

Dr. Shigeru Suga

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2021 in Microorganisms
Verified
Journal Article
Open access
PDF file
JBJulia Bennett
Julia Bennett
MHMarissa K. Hetrich
Marissa K. Hetrich
MQMaria Garcia Quesada
Maria Garcia Quesada
JSJenna Sinkevitch
Jenna Sinkevitch
MKMaria Deloria Knoll
Maria Deloria Knoll
TTthe PSERENADE Team
the PSERENADE Team
Streptococcus pneumoniae serotype 1 (ST1) was an important cause of invasive pneumococcal disease (IPD) globally before the introduction of pneumococcal conjugate vaccines (PCVs) containing ST1 antigen. The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project gathered ST1 IPD surveillance data from sites globally and aimed to estimate PCV10/13 impact on ST1 IPD incidence. We estimated ST1 IPD incidence rate ratios (IRRs) comparing the pre-PCV10/13 period to each post-PCV10/13 year by site using a Bayesian multi-level, mixed-effects Poisson regression and all-site IRRs using a linear mixed-effects regression (N = 45 sites). Following PCV10/13 introduction, the incidence rate (IR) of ST1 IPD declined among all ages. After six years of PCV10/13 use, the all-site IRR was 0.05 (95% credibility interval 0.04–0.06) for all ages, 0.05 (0.04–0.05) for <5 years of age, 0.08 (0.06–0.09) for 5–17 years, 0.06 (0.05–0.08) for 18–49 years, 0.06 (0.05–0.07) for 50–64 years, and 0.05 (0.04–0.06) for ≥65 years. PCV10/13 use in infant immunization programs was followed by a 95% reduction in ST1 IPD in all ages after approximately 6 years. Limited data availability from the highest ST1 disease burden countries using a 3 + 0 schedule constrains generalizability and data from these settings are needed.

13 April 2023 in Viruses
Verified
Journal Article
Open access
PDF file
AKAsa Kitamura
Asa Kitamura
KTKuniaki Toriyabe
Kuniaki Toriyabe
MHMiki Hagimoto-Akasaka
Miki Hagimoto-Akasaka
KHKyoko Hamasaki-Shimada
Kyoko Hamasaki-Shimada
MIMakoto Ikejiri
Makoto Ikejiri
TITomoaki Ikeda
Tomoaki Ikeda
Cytomegalovirus (CMV) is associated with congenital infections. We aimed to validate the revised CMV immunoglobulin (Ig) M titer cutoff for IgG avidity measurements as a reflex test in maternal screening to identify women with primary CMV infection and newborn congenital cytomegalovirus (cCMV). We screened maternal CMV antibodies (the Denka assay) in Japan, from 2017 to 2019, using a revised IgM cutoff (≥4.00 index). Participants were tested for IgG and IgM antibodies, and for IgG avidity if IgM levels exceeded the cutoff. We compared these with corresponding results from 2013 to 2017 based on the original cutoff (≥1.21) and recalculated using the revised cutoff. Newborn urine CMV DNA tests were performed for women with low avidity (≤35.0%). Among 12,832 women screened in 2017–2019, 127 (1.0%) had IgM above the revised cutoff. Thirty-five exhibited low avidity, and seven infants developed cCMV. Of 19,435 women screened in 2013–2017, 184 (1.0%) had IgM above the revised cutoff, 67 had low avidity, and 1 had cCMV. The 2017–2019 results were not significantly different from the 2013–2017 results. The revised IgM cutoff improves maternal screening in identifying primary infection and newborn cCMV; however, further study related to other assays than Denka is required.

12 December 2025 in Journal of Medical Microbiology
Verified
Journal Article
Open access
SNSatoshi Nakano
Satoshi Nakano
TFTakao Fujisawa
Takao Fujisawa
SKShota Koide
Shota Koide
YSYo Sugawara
Yo Sugawara
BCBin Chang
Bin Chang
MSMotoyuki Sugai
Motoyuki Sugai
Introduction. Streptococcus pneumoniae remains a major pathogen causing invasive diseases in children worldwide. Although pneumococcal conjugate vaccines (PCVs) have significantly reduced the disease burden, non-vaccine serotypes and antimicrobial resistance continue to be of concern. Hypothesis/ Gap Statement. The epidemiology of paediatric invasive pneumococcal disease (IPD) and antimicrobial resistance patterns in Japan following the coronavirus disease 2019 pandemic and prior to the introduction of PCV15 and PCV20 has not been fully characterized. Aim. To investigate the recent distribution of pneumococcal serotypes, antimicrobial susceptibility and genetic characteristics of isolates derived from paediatric patients in Japan from 2020 to 2023. Methodology. We conducted a nationwide, prospective surveillance study from March 2020 to April 2023. A total of 151 pneumococcal isolates (126 from IPD cases and 25 from non-IPD cases) were collected from children under 15 years of age. Serotyping, antimicrobial susceptibility testing and whole-genome sequencing were performed to assess epidemiological and genomic features. Results. No patient mortality was reported, but sequelae were observed in 4 (3.2%) of 125 IPD patients. The most common serotypes in IPD were 15B/C (23.0%), 15A (11.1%) and 24B (10.3%). Among 126 IPD isolates, the vaccine coverage rates for PCV13, 15 and 20 were 0.8, 13.5 and 42.1%, respectively. Overall resistance rates to penicillin (PEN), cefotaxime, meropenem (MEM) and erythromycin (ERY) were 31.8, 15.9, 18.5 and 88.7%, respectively. Serotypes 15A-CC63 and 35B-CC558 showed high resistance rates to β -lactams, including MEM. Genomic analysis revealed that the predominant genotypes were 15B/C-CC199, 15A-CC63, 24B-CC2754 and 10A-CC5236. Conclusion. Non-vaccine and PEN-, MEM- and ERY-resistant clones, particularly 15A-CC63 and 35B-CC558, were prevalent among paediatric pneumococci in Japan. Even with PCV20, less than half of the IPD isolates were covered; this underscores the need for ongoing genomic surveillance, antimicrobial stewardship and consideration of expanded-valency vaccines targeting additional serotypes, such as 15A and 35B.

30 July 2023 in Viruses
Verified
Journal Article
Open access
PDF file
ETEtsuhisa Takahashi
Etsuhisa Takahashi
TSTakako Sawabuchi
Takako Sawabuchi
THTetsuya Homma
Tetsuya Homma
YFYosuke Fukuda
Yosuke Fukuda
HSHironori Sagara
Hironori Sagara
HKHiroshi Kido
Hiroshi Kido
Conventional serum antibody titer, which expresses antibody level, does not provide antigen binding avidity of the variable region of the antibody, which is essential for the defense response to infection. Here, we quantified anti-SARS-CoV-2 antibody binding avidity to the receptor-binding domain (RBD) by competitive binding-inhibition activity (IC50) between SARS-CoV-2 S1 antigen immobilized on the DCP microarray and various RBD doses added to serum and expressed as 1/IC50 nM. The binding avidity analyzed under equilibrium conditions of antigen–antibody binding reaction is different from the avidity index measured with the chaotropic agent, such as urea, under nonequilibrium and short-time conditions. Quantitative determination of the infection-protection potential of antibodies was assessed by ABAT (antigen binding avidity antibody titer), which was calculated by the quantity (level) × quality (binding avidity) of antibodies. The binding avidity correlated strongly (r = 0.811) with cell-based virus-neutralizing activity. Maturation of the protective antibody induced by repeated vaccinations or SARS-CoV-2 infection was classified into three categories of ABAT, such as an initial, low, and high ABAT. Antibody maturity correlated with the clinical severity of COVID-19. Once a mature high binding avidity was achieved, it was maintained for at least 6–8 months regardless of the subsequent change in the antibody levels.

29 April 2023 in Viruses
Verified
Journal Article
Open access
PDF file
KTKuniaki Toriyabe
Kuniaki Toriyabe
AKAsa Kitamura
Asa Kitamura
MHMiki Hagimoto-Akasaka
Miki Hagimoto-Akasaka
MIMakoto Ikejiri
Makoto Ikejiri
SSShigeru Suga
Shigeru Suga
TITomoaki Ikeda
Tomoaki Ikeda
This study evaluated the impact of the coronavirus disease 2019 (COVID-19) pandemic on the occurrence of maternal primary cytomegalovirus (CMV) infection in Japan. We performed a nested case-control study using data from maternal CMV antibody screening under the Cytomegalovirus in Mother and infant-engaged Virus serology (CMieV) program in Mie, Japan. Pregnant women with negative IgG antibodies at ≤20 weeks of gestation who were retested at ≥28 weeks were enrolled. The study period was divided into 2015–2019 as the pre-pandemic and 2020–2022 as the pandemic period, and the study site included 26 institutions conducting the CMieV program. The incidence rate of maternal IgG seroconversion was compared between the pre-pandemic (7008 women enrolled) and pandemic (2020, 1283 women enrolled; 2021, 1100 women; and 2022, 398 women) periods. Sixty-one women in the pre-pandemic period and five, four, and five women during 2020, 2021, and 2022, respectively, showed IgG seroconversion. The incidence rates in 2020 and 2021 were lower (p < 0.05) than that in the pre-pandemic period. Our data suggest a transient decrease in the incidence of maternal primary CMV infection in Japan during the COVID-19 pandemic, which could be due to prevention and hygiene measures taken at the population level.

31 July 2026 in Microbial Genomics
Verified
Journal Article
Open access
SKShota Koide
Shota Koide
SNSatoshi Nakano
Satoshi Nakano
TFTakao Fujisawa
Takao Fujisawa
YIYutaka Ito
Yutaka Ito
BCBin Chang
Bin Chang
MSMotoyuki Sugai
Motoyuki Sugai
Following the introduction of the 7-valent pneumococcal conjugate vaccine (PCV7), serotype 19A Streptococcus pneumoniae emerged as a major cause of paediatric pneumococcal disease in Japan. Unlike global trends, in which multidrug-resistant serotype 19A-sequence type (ST)320 predominated, serotype 19A-ST2331 became one of the dominant lineages in Japan. The evolutionary origins of serotype 19A-ST2331 and the reasons for its domestic success remain unclear. To investigate the evolutionary origin and dissemination of the serotype 19A-ST2331 lineage, we analysed whole-genome sequences of 42 clonal complex (CC)2331 isolates collected in Japan between 2004 and 2017 and compared them with 825 genetically related global isolates. Phylogenetic analysis showed that Japanese serotype 19A-ST2331 isolates formed a distinct Japan-associated cluster within Global Pneumococcal Sequence Cluster 32 that was closely related to the globally disseminated Pneumococcal Molecular Epidemiology Network (PMEN)34 clone, typically represented by serotype 12F-ST218. Among the 42 Japanese CC2331 isolates, 40 were serotype 19A, whereas only two non-19A isolates were identified. Serotype 19A was absent from the 825 non-Japanese isolates, indicating that serotype 19A-ST2331 represents a globally rare, Japan-specific lineage. Most Japanese isolates remained susceptible to β-lactams, whereas 83.3% were erythromycin-resistant and carried either mefA/E or ermB . A highly clonal mefA/E -positive subclade was dated to a most recent common ancestor at ∼1998.5. These findings indicate that serotype 19A-ST2331 emerged before 2000 from an ST218-related ancestor through serotype switching and subsequently underwent local expansion in Japan. Although the ancestral intermediate was not represented in the present collection, the successful establishment of this clone may have been facilitated by the combined selective advantages conferred by the serotype 19A capsule and macrolide resistance in the post-PCV7 setting in Japan.